Evaluation of a no-pretreatment cyclosporin a assay on the Dade Behring Dimension RxL clinical chemistry analyzer

Clinical Chemistry

Volumn 48, Issue 7, 2002, Pages 1059-1065

  Terrell, Andrea R ^a   Daly, Thomas M ^a   Hock, Karl G ^a   Kilgore, Daniel C ^a   Wei, Tie Q ^a   Hernandez, Sharon ^a   Weibe, Don ^a   Fields, Leona ^a   Shaw, Leslie M ^a   Scott, Mitchell G ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 18444406859     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinchem/48.7.1059     Document Type: Article

References (36)

1. Pharmacology of cyclosporine. VI. Cellular activation: Regulation of intracellular events by cyclosporine
2. The mechanism of action of cyclosporin A and FK506
3. Cyclosporin A specifically inhibits function of nuclear proteins involved in T cell activation
4. Nuclear association of a T-cell transcription factor blocked by FK-506 and cyclosporin A
5. Toxic effects of immunosuppressive drugs: Mechanisms and strategies for controlling them
6. Cyclosporin A acute encephalopathy and seizure syndrome in childhood: Clinical features and risk of seizure recurrence
7. Cyclosporine: Structure, pharmacokinetics, and therapeutic drug monitoring
8. Cyclosporin clinical pharmacokinetics
9. Pharmacokinetic drug interactions with cyclosporine (Part 1)
10. Pharmacokinetic drug interactions with cyclosporine (Part 2)
11. Pharmacokinetics of cyclosporine in human renal transplantation
12. Pharmacokinetic monitoring of cyclosporine
13. Routine monitoring of cyclosporine in whole blood and in kidney tissue using high performance liquid chromatography
14. Cyclosporine nephrotoxicity is minimized by adjusting dosage on the basis of drug concentration in blood
15. Adjustment of cyclosporine dosage in renal transplant patients based on concentration measured specifically in whole blood: Clinical outcome results and diagnostic utility
16. Role of lipoproteins and erythrocytes in the in vitro binding and distribution of cyclosporin A in the blood
17. The transport of cyclosporine in association with plasma lipoproteins in heart and liver transplant patients
18. Effects of sample preparation on concentrations of cyclosporine A measured in plasma
19. Temperature dependency of apparent cyclosporine A concentration in plasma
20. Effect of hematocrit on cyclosporine (cyclosporine A) in whole blood and plasma of renal-transplant patients
21. Distribution of cyclosporin A metabolites among plasma and cells in whole blood: Effect of temperature, hematocrit, and metabolic concentration
22. Methodological and clinical aspects of cyclosporin monitoring: Report of the Association of Clinical Biochemists task force
23. Critical issues in cyclosporine monitoring: Report of the task force on cyclosporine monitoring
24. Canadian consensus meeting on cyclosporine monitoring: Report of the consensus panel
25. Lake Louise Consensus Conference on cyclosporin monitoring in organ transplantation: Report of the consensus panel
26. Consensus document: Hawk's Cay meeting on therapeutic drug monitoring of cyclosporine
27. Identification and analysis of nine metabolites of cyclosporine in whole blood by liquid chromatography. 1: Purification of analytical standards and optimization of the assay
28. Cyclosporin whole blood immunoassays (AxSYM, CEDIA, and Emit): A critical overview of performance characteristics and comparison with HPLC
29. Monitoring cyclosporine in liver-transplant recipients: Effects of clinical status on the performance of two monoclonal antibody-based methods
30. Performance and specificity of monoclonal immunoassays for cyclosporine monitoring: How specific is specific?
31. Simultaneous simple and fast quantification of three major immunosuppressants by liquid chromatography-tandem mass-spectrometry
32. C2 monitoring strategy for optimising cyclosporin immunosuppression from the Neoral formulation
33. Purification and identification of the rifampicin-inducible human liver cytochrome P450 (cyclosporin A oxidase) as a product of P450IIIA gene subfamily
34. Cyclosporine pharmacokinetics in liver transplant recipients: Evaluation of results using both polyclonal radioimmunoassay and liquid chromatographic analysis
35. Cyclosporin metabolite pattern in blood and urine of liver graft recipients